Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus

D. Abdelhakam, P. R. Young, M. K. Jain, A. Nassar, J. A. Copland, W. Tan

Research output: Contribution to journalArticle

Abstract

Bladder cancer is the sixth most common malignancy in the United States. Cisplatin combination regimens are first line therapy for patients with metastatic urothelial bladder cancer who are eligible candidates and no treatments have shown to improve outcome compared to chemotherapy for the past 20 years. Significant advances were made in past 2–3 years and the most significant was the introduction of checkpoints inhibitors in bladder cancer treatment. We present a patient diagnosed with metastatic urothelial carcinoma who progressed while on cisplatin/gemcitabine chemotherapy in the form of oligometastasis to the bone. He has achieved a durable complete response with atezolizumab.

Original languageEnglish (US)
Article number101130
JournalUrology Case Reports
Volume30
DOIs
StatePublished - May 2020

Keywords

  • Atezolizumab
  • Checkpoint inhibitors
  • Cisplatin chemotherapy
  • Metastatic urothelial cancer
  • PD-1/PD-L1

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus'. Together they form a unique fingerprint.

  • Cite this